Proteasome Assay Kits

Assay Principle

The proteasome, most commonly studied as the 20S core particle or the full 26S complex, is the central protein degradation machine of the ubiquitin-proteasome system, responsible for clearing misfolded and short-lived regulatory proteins and a major target in oncology drug discovery given its role in cancer cell survival. A proteasome assay typically measures one or more of its three catalytic activities (chymotrypsin-like, trypsin-like, and caspase-like) using short peptide substrates conjugated to a fluorogenic or luminogenic reporter group; proteasomal cleavage releases the reporter, generating a signal (commonly measured using an AMC-based fluorophore around Ex/Em 350/440 nm, or through a luciferase-coupled luminescent readout) proportional to proteolytic activity. Because each catalytic activity has its own preferred peptide sequence, kits are typically built around a substrate selective for the activity of interest, most often the chymotrypsin-like activity given its central role in most proteasome inhibitor screening.

Protocol highlights and purchasing considerations

Protocol Highlights

Kits are generally validated for cell lysates and purified 20S or 26S proteasome preparations, with assay times ranging from under an hour for simple fluorogenic endpoint formats to longer kinetic protocols when characterizing inhibitor dose-response curves. Because proteasome activity is sensitive to ATP availability in the 26S complex and can be confounded by non-proteasomal proteases present in crude lysates, including a selective proteasome inhibitor (such as MG-132 or bortezomib) as a background-subtraction control is standard practice to confirm that measured signal reflects genuine proteasomal cleavage. Researchers should also account for the fact that fluorogenic AMC-based substrates are prone to nonspecific cleavage by other cellular proteases, making inhibitor-controlled background subtraction particularly important in complex lysates compared with purified enzyme preparations.

Assay Kit Purchasing Considerations

The primary choice for measuring proteasome activity is fluorometric versus luminescent detection, and this should be guided by required sensitivity and instrumentation: luminescent formats generally offer a wider dynamic range and lower background in complex lysates, making them well suited to high-throughput inhibitor screening, while fluorometric kits remain a cost-effective option for routine activity profiling. For proteasome inhibitor drug discovery programs, confirming that a kit's assay window, Z-factor, and validated substrate specificity have been established for high-throughput screening formats is an important consideration before committing to a large compound library campaign. Researchers studying a specific catalytic activity (chymotrypsin-like, trypsin-like, or caspase-like) should also confirm that a kit's substrate is selective for that activity and does not report a composite signal from multiple catalytic sites, since this distinction matters considerably for mechanistic studies of proteasome inhibitors. As with any activity assay, it's good practice to review the full protocol before deciding on a kit, since the manual often reveals practical details, such as incubation times, control requirements, and data analysis steps, that aren't captured in the product summary alone.